98%
921
2 minutes
20
The detection and identification of botulinum neurotoxins (BoNT) is complex due to the existence of seven serotypes, derived mosaic toxins and more than 40 subtypes. Expert laboratories currently use different technical approaches to detect, identify and quantify BoNT, but due to the lack of (certified) reference materials, analytical results can hardly be compared. In this study, the six BoNT/A1-F1 prototypes were successfully produced by recombinant techniques, facilitating handling, as well as improving purity, yield, reproducibility and biosafety. All six BoNTs were quantitatively nicked into active di-chain toxins linked by a disulfide bridge. The materials were thoroughly characterized with respect to purity, identity, protein concentration, catalytic and biological activities. For BoNT/A₁, B₁ and E₁, serotypes pathogenic to humans, the catalytic activity and the precise protein concentration were determined by Endopep-mass spectrometry and validated amino acid analysis, respectively. In addition, BoNT/A₁, B₁, E₁ and F₁ were successfully detected by immunological assays, unambiguously identified by mass spectrometric-based methods, and their specific activities were assigned by the mouse LD50 bioassay. The potencies of all six BoNT/A1-F1 were quantified by the ex vivo mouse phrenic nerve hemidiaphragm assay, allowing a direct comparison. In conclusion, highly pure recombinant BoNT reference materials were produced, thoroughly characterized and employed as spiking material in a worldwide BoNT proficiency test organized by the EQuATox consortium.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690111 | PMC |
http://dx.doi.org/10.3390/toxins7124861 | DOI Listing |
Dermatol Surg
September 2025
Etre Cosmetic Dermatology and Laser Center, New Orleans, Louisiana.
Background: Botulinum neurotoxins in aesthetic medicine require reconstitution, which may cause administration errors.
Objective: To evaluate liquid nivobotulinumtoxinA treatment of lateral canthal lines (LCL) and glabellar lines (GL).
Materials And Methods: Participants with moderate-to-severe LCL with/without moderate-to-severe GL were enrolled in 2 double-blind randomized clinical trials.
Brain Behav
September 2025
Department of Neurology, Huai'an First People's Hospital, the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
Background And Purpose: Parkinson's disease (PD), a prevalent neurodegenerative disorder characterized by motor impairments, frequently accompanied by neuropsychiatric symptoms that significantly impair daily functioning and quality of life. The present study aimed to assess the efficacy of botulinum toxin A (BTX-A) in alleviating neuropsychiatric symptoms among PD patients.
Methods: This is an open-label, nonrandomized controlled trial.
Eur J Pediatr
September 2025
Department of Paediatric Otolaryngology, Royal Hospital for Children, 1345 Govan Road, Glasgow, G51 4TF, UK.
Unlabelled: Drooling is a common problem in children with neurodisability, and refractory cases may require surgery. Our aim was to assess whether a child's response to salivary botulinum toxin injections would predict success or failure from subsequent surgical intervention. Retrospective case note review of all children undergoing drooling surgery between 1st January 2007 and 31st December 2023 at the Royal Hospital for Children, Glasgow.
View Article and Find Full Text PDFbioRxiv
August 2025
Department of Bacteriology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa 920-8640, Japan.
Botulinum toxins (BoNTs) are the most potent known bacterial toxins. The BoNT complex from B-Okra (large progenitor toxin complex (L-PTC)/B, hyper-oral-toxic) exerts at least 80-fold higher oral toxicity in mice compared with that from serotype A1 (L-PTC/A, non-hyper-oral-toxic). Here, we showed that L-PTC/B was predominantly absorbed through enterocytes, whereas L-PTC/A targeted intestinal microfold cells.
View Article and Find Full Text PDFSci Adv
August 2025
Department of Physiology and Biophysics, University of California, Irvine, CA 92697, USA.
Botulinum neurotoxin serotype A (BoNT/A) is naturally produced by bacteria along with four nontoxic neurotoxin-associated proteins (NTNH, HA70, HA33, and HA17), forming a bimodular large progenitor toxin complex (L-PTC). The BoNT/A-NTNH complex protects the toxin from adverse environment, while the complex consisting of HA proteins facilitates toxin absorption during oral intoxication. How these two independent modules assemble into the L-PTC remains unclear.
View Article and Find Full Text PDF